[출처/시간] MT Newswires - 7:42 AM ET, 05/27/2026
07:42 AM EDT, 05/27/2026 (MT Newswires) -- BioNTech (BNTX) has an average rating of overweight and mean price target of $125.50, according to analysts polled by FactSet.
장중 · Aug 17, 2026, EDT
·
정보기술
·
매수
UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117
[출처/시간] MT Newswires - 7:42 AM ET, 05/27/2026 07:42 AM EDT, 05/27/2026 (MT Newswires) -- BioNTech (BNTX) has an average rating of overweight and mean price target of $125.50, according to analysts polled by FactSet. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
ADVERTISEMENT
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www.mtnewswires.com/contact-us)
리포트 잘 봤습니다. 경쟁사 비교 차트가 한눈에 들어와서 좋네요. 다음 분기 가이던스가 어떻게 나올지 궁금합니다.
같은 섹터의 ETF 흐름도 함께 보면 더 좋을 것 같습니다.
의견 감사합니다. 곧 섹터 ETF 비교 차트를 별도 임베드로 추가할 예정입니다.